Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation
- PMID: 12151430
- DOI: 10.1093/humrep/17.8.2016
Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation
Abstract
Background: The effect of LH levels on stimulation day 8 on ovarian response and pregnancy outcome were evaluated in women receiving pituitary down-regulation with GnRH agonists (0.8 mg Suprefact) s.c. daily until pituitary down-regulation and 0.4 mg/day during ovarian stimulation) and ovarian stimulation with recombinant FSH.
Methods: Blood samples were prospectively collected from a total of 207 normal women undergoing assisted reproduction and analysed retrospectively. Based on LH levels on stimulation day 8 patients were divided into four groups: <0.5, 0.51-1.0, 1.01-1.5, >1.51 IU/l.
Results: Estradiol levels on day 8 and estradiol per oocyte retrieved showed a highly significant correlation with LH concentrations on day 8. The total consumption of exogenous FSH and duration of gonadotrophin stimulation was inversely related to LH levels on day 8 (P < 0.002). The frequencies of fertilization and clinical pregnancies were superior in the two middle groups. Only 12% of the patients showed LH levels <0.5 IU/l, which, however, may be explained by the particular mode and doses of GnRH agonist used.
Conclusions: Circulating levels of LH on day 8 have a significant impact on ovarian response and pregnancy outcome. LH should neither be too high nor too low. The mode of administration and the dose of the GnRH agonist used may determine the number of women who experience LH levels below 0.5 IU/l.
Similar articles
-
Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.J Clin Endocrinol Metab. 2003 Sep;88(9):4186-92. doi: 10.1210/jc.2002-021953. J Clin Endocrinol Metab. 2003. PMID: 12970285 Clinical Trial.
-
A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.Hum Reprod. 2006 Oct;21(10):2645-9. doi: 10.1093/humrep/del219. Epub 2006 Jun 19. Hum Reprod. 2006. PMID: 16785261
-
LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH.Hum Reprod. 2003 Dec;18(12):2689-97. doi: 10.1093/humrep/deg506. Hum Reprod. 2003. PMID: 14645193
-
Outlook: who needs LH in ovarian stimulation?Reprod Biomed Online. 2006 May;12(5):599-607. doi: 10.1016/s1472-6483(10)61186-8. Reprod Biomed Online. 2006. PMID: 16790105 Review.
-
Role of LH and FSH in ovarian function.Mol Cell Endocrinol. 2000 Mar 30;161(1-2):25-30. doi: 10.1016/s0303-7207(99)00219-1. Mol Cell Endocrinol. 2000. PMID: 10773387 Review.
Cited by
-
Ovarian response determines the luteinizing hormone suppression threshold for patients following the gonadotrophin releasing hormone antagonist protocol: A retrospective cohort study.Heliyon. 2023 Dec 20;10(1):e23933. doi: 10.1016/j.heliyon.2023.e23933. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187350 Free PMC article.
-
LH level on ovulation trigger day has a different impact on the outcomes of agonist and antagonist regimens during in vitro fertilization.J Ovarian Res. 2023 Jan 27;16(1):26. doi: 10.1186/s13048-023-01110-8. J Ovarian Res. 2023. PMID: 36707867 Free PMC article.
-
Effect of Exogenous Luteinizing Hormone (LH) Supplementation on Clinical Pregnancy of Patients Receiving Long-Acting Gonadotropin-Releasing Hormone Agonist (GnRHa) Cycles: A Retrospective Cohort Study.Int J Womens Health. 2022 Dec 13;14:1691-1700. doi: 10.2147/IJWH.S388726. eCollection 2022. Int J Womens Health. 2022. PMID: 36536609 Free PMC article.
-
Progestin-primed ovarian stimulation protocol with or without clomiphene citrate for poor ovarian responders: a retrospective cohort study.BMC Womens Health. 2022 Dec 17;22(1):527. doi: 10.1186/s12905-022-02126-w. BMC Womens Health. 2022. PMID: 36528555 Free PMC article.
-
Luteinizing hormone-based modified GnRH antagonist protocol in normal responders undergoing in vitro fertilization treatment: A multi-center randomized controlled trial.Front Endocrinol (Lausanne). 2022 Aug 11;13:922950. doi: 10.3389/fendo.2022.922950. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36034460 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
